LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)
China · Delayed Price · Currency is CNY 7.66
-0.05 (-0.65%)
Jul 30, 2026, 1:45 PM CST
SHE:002644 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,937 | 4,412 | 3,942 | 4,979 | 4,764 | 5,127 | |
Market Cap Growth | -20.68% | 11.92% | -20.82% | 4.50% | -7.07% | 41.81% |
Enterprise Value | 3,424 | 4,019 | 3,655 | 4,750 | 4,553 | 4,850 |
Last Close Price | 7.71 | 8.62 | 7.69 | 9.66 | 9.21 | 9.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 74.99 | 89.66 | 65.63 | 74.10 | 43.85 | 54.98 |
Forward PE | - | 53.88 | 53.88 | 53.88 | 53.88 | 53.88 |
PS Ratio | 4.32 | 4.82 | 4.02 | 4.28 | 4.57 | 6.27 |
PB Ratio | 2.11 | 2.38 | 2.17 | 2.82 | 2.74 | 3.15 |
P/TBV Ratio | 2.23 | 2.52 | 2.31 | 3.01 | 2.92 | 3.33 |
P/FCF Ratio | 17.95 | 26.68 | 153.42 | 115.14 | 105.68 | - |
P/OCF Ratio | 16.98 | 23.99 | 101.12 | 75.77 | 55.01 | 432.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.76 | 4.39 | 3.73 | 4.08 | 4.37 | 5.93 |
EV/EBITDA Ratio | 27.43 | 32.55 | 39.19 | 41.56 | 39.61 | 51.83 |
EV/EBIT Ratio | 49.96 | 57.86 | 83.92 | 75.52 | 68.88 | 106.24 |
EV/FCF Ratio | 15.61 | 24.30 | 142.24 | 109.85 | 101.00 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 | 0.04 |
Debt / EBITDA Ratio | 0.23 | 0.36 | 0.43 | 0.46 | 0.48 | 0.73 |
Debt / FCF Ratio | 0.13 | 0.28 | 1.59 | 1.22 | 1.23 | - |
Net Debt / Equity Ratio | -0.29 | -0.26 | -0.20 | -0.20 | -0.20 | -0.19 |
Net Debt / EBITDA Ratio | -4.34 | -3.88 | -3.83 | -3.09 | -2.99 | -3.27 |
Net Debt / FCF Ratio | -2.45 | -2.90 | -13.90 | -8.17 | -7.64 | 14.62 |
Asset Turnover | 0.37 | 0.37 | 0.39 | 0.45 | 0.42 | 0.35 |
Inventory Turnover | 1.97 | 1.93 | 1.92 | 2.19 | 2.37 | 2.31 |
Quick Ratio | 2.30 | 2.31 | 2.26 | 1.79 | 1.66 | 1.95 |
Current Ratio | 3.04 | 3.03 | 3.22 | 2.65 | 2.40 | 2.76 |
Return on Equity (ROE) | 2.68% | 2.56% | 3.44% | 3.88% | 6.49% | 5.82% |
Return on Assets (ROA) | 1.72% | 1.73% | 1.09% | 1.53% | 1.67% | 1.20% |
Return on Invested Capital (ROIC) | 3.68% | 3.54% | 2.70% | 3.73% | 4.07% | 3.01% |
Return on Capital Employed (ROCE) | 3.20% | 3.30% | 2.10% | 3.10% | 3.20% | 2.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.33% | 1.11% | 1.52% | 1.35% | 2.28% | 1.82% |
FCF Yield | 5.57% | 3.75% | 0.65% | 0.87% | 0.95% | -0.41% |
Dividend Yield | 0.26% | 0.23% | 0.16% | 0.31% | 0.54% | 0.10% |
Payout Ratio | 13.67% | 14.27% | 26.56% | 41.59% | 6.53% | 65.88% |
Buyback Yield / Dilution | 0.02% | 0.07% | -0.05% | 0.01% | 0.03% | -0.00% |
Total Shareholder Return | 0.28% | 0.30% | 0.11% | 0.32% | 0.57% | 0.10% |